[Current developments and perspectives in targeted therapies].
Many different approaches for improving the prognosis of patients with advanced non-small-cell lung cancer (NSCLC) are currently being investigated. This article discusses the significance of maintenance therapy after primary chemotherapy and reviews study data on second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), inhibitors of insulin-like growth factor receptors (IGFR), vascular-disrupting agents (VDAs) and multi-TKIs of vascular endothelial growth factor receptors (VEGFR). The article also looks at the future prospects of using genetic markers in the field of NSCLC.
Klinik für Pneumologie, Medizinische Hochschule Hannover, Deutschland.
Nicolas
N
Dickgreber
Rudolf M
RM
Huber
Martin
M
Reck
Niels
N
Reinmuth
Wolfgang
W
Schütte
Monika
M
Serke
Jürgen
J
Wolf
D000359:Aftercare; D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics; D004252:DNA Mutational Analysis; D016503:Drug Delivery Systems; D015507:Drugs, Investigational / Q000008:administration & dosage* / Q000009:adverse effects; D066246:ErbB Receptors / Q000032:analysis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors / Q000235:genetics; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000235:genetics
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D005819:Genetic Markers; D015514:Oncogene Proteins, Fusion; D017451:Receptors, Somatomedin; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor